Taiwanese scientists have created the first genetic treatment approved by the EU for L-amino acid decarboxylase (AADC) deficiency, an extremely rare and fatal disorder, they said yesterday.
The treatment, given the trade name Upstaza, was on Wednesday approved for market by the European Medicines Agency, the EU’s main drug regulator, the National Taiwan University Hospital-based research team told a news conference.
AADC deficiency inhibits the secretion of an enzyme that is key to making dopamine, said team leader Hu Wu-liang (胡務亮), who is also the director of the hospital’s pediatrics and genetic medicine departments.
Photo: Yang Yuan-ting, Taipei Times
The disorder primarily manifests in infants and severely impedes their ability to develop speech, walk, sleep or swallow food, with death typically occurring before the age of five, he said.
The condition affects about 700 children in Taiwan, comprising 30 percent of the world’s AADC cases, suggesting that the genetic trait causing the disorder has a strong regional prevalence, Hu said.
As cases are rare in North America and Europe, where most of the world’s drugs are made, there was a lack of impetus among Western drugmakers to develop a treatment for the condition, he said.
In response, Hu launched an initiative to find a cure, and received the university hospital’s approval in his effort, which led to the creation of Upstaza in 2010, he said.
Upstaza is a one-time treatment that introduces a functioning AADC gene to the patient by directly injecting it into the patient’s brain, using modified adeno-associated viruses as the vehicle mechanism, Hu said.
An affected person with the replaced AADC gene would gain the ability to produce dopamine, leading to a partial recovery of bodily functions and providing hope for a normal life, Hu said, adding that the therapy has been proven by a 12-year tracking study.
A two-year-old patient who had been bedridden and unable to speak gained the ability to run, use staircases unassisted and verbally communicate within four years of receiving the treatment, he said.
“Using the technology, the hospital successfully treated the 30 Taiwanese patients [with AADC] to bring hope to their families,” Hu said.
The rights to the drug have been transferred to US-based PTC Therapeutics, which is exploring the possibility of applying Upstaza’s underlying viral and surgical technology to treat other conditions affecting the brain, he said.
Upstaza cannot be used for Parkinson’s disease, as the treatment requires intact neurons to work, Hu added.
SELF-RELIANCE: Taiwan would struggle to receive aid in the event of an invasion, so it must prepare to ‘hold its own’ for the first 70 days of a war, a defense expert said Taiwan should strengthen infrastructure, stock up on reserves and step up efforts to encourage Taiwanese to fight against an enemy, legislators and experts said on Tuesday last week. The comments sought to summarize what the nation should learn from the Russian invasion of Ukraine, which has exceeded 300 days, since Feb. 24 last year. Institute of National Defense and Security Research fellow Su Tzu-yun (蘇紫雲) said that the war in Ukraine highlighted the importance of being ready for war. Taiwan’s development of an “asymmetrical warfare” doctrine and extending mandatory conscription to one year is a good start to preparation of defense against a
 - Copy.jpg)
The Tourism Bureau plans to offer incentives to attract international tourists as the nation plans to gradually lift all travel restrictions to contain COVID-19, Minister of Transportation and Communications Wang Kwo-tsai (王國材) said yesterday. The incentives would be funded by surplus national tax revenue from last year, Wang said. The funding could be appropriated after the legislature passes draft special statutes governing the use of the surplus tax revenue in the upcoming legislative session, he said. Of the NT$450 billion (US$14.97 billion) in surplus tax revenue, the government plans to spend NT$100 billion on seven categories of projects to bolster Taiwan’s
The Central Epidemic Command Center yesterday said it would delay the lifting of the indoor mask mandate, citing public health considerations and ongoing discussions on how the policy should be implemented. Earlier this week, Centers for Disease Control Deputy Director-General Chuang Jen-hsiang (莊人祥), who is the CECC’s spokesman, said officials from several ministries were working on the policy and an announcement would be made yesterday. However, Deputy Minister of Health and Welfare Victor Wang (王必勝), who heads the CECC, yesterday said that the policy was still under review. Wang said its implementation would be “delayed slightly” due to three main factors. First, the center
Retired US admiral Philip Davidson, who in 2021 warned of a potential Chinese conflict with Taiwan by 2027, is in Taiwan to discuss regional security-related issues. He was the head of the US Indo-Pacific Command at the time. Davidson is part of a six-member delegation from US-based think tank the National Bureau of Asian Research that arrived in Taiwan on Monday, the Ministry of Foreign Affairs (MOFA) said yesterday. The group is scheduled to meet with President Tsai Ing-wen (蔡英文), and visit two government-funded non-governmental organizations — the Institute for National Defense and Security Research and Taiwan Foundation for Democracy — to exchange
RSS